Recent advancements in antibody-based therapies are significantly enhancing cancer treatment options. Notably, researchers at King’s College London have developed an innovative antibody that stimulates the immune system to target cancer cells, effectively slowing tumor growth in treatment-resistant breast and ovarian cancers. This approach represents a promising avenue for patients unresponsive to existing treatments.
In the realm of multiple myeloma, talquetamab—a bispecific antibody targeting GPRC5D and CD3—has emerged as a novel therapeutic option. Approved by the FDA in August 2023, talquetamab directs T-cells to attack cancer cells, offering hope for patients with relapsed or refractory multiple myeloma. Click for More Details
